CJC-1295: Evidence, Legal Status & Verified Clinics

CJC-1295 is a synthetic GHRH analogue often paired with ipamorelin. See what the evidence and 2026 legal status say, why it's WADA-banned in sport, and what to ask clinics that reference it. This page is informational and does not diagnose, prescribe, or recommend therapies.

Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.

Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.

Common contexts

  • Referenced in growth hormone secretagogue and performance-focused clinic contexts.
  • Some clinics list CJC-1295 within broader recovery, body composition, or anti-aging pathways.
  • It is often grouped with ipamorelin rather than presented as a standalone offering.

Safety information

  • Human evidence and regulatory status are more limited than for mainstream prescription medicines.
  • Ask clinics what baseline testing, clinician oversight, and monitoring are included before considering any protocol.
  • Be cautious of providers that present CJC-1295 as risk-free or universally appropriate.

Quick summary

  • CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue, studied for its effect on growth-hormone and IGF-1 levels and often paired with ipamorelin.
  • It is not an approved medicine: it has never been FDA-approved, the UK MHRA treats it as unlicensed, and its US compounding status was an area of regulatory uncertainty through 2026.
  • It is prohibited in sport at all times by WADA as a GHRH analogue.
  • Clinics reference it in performance, recovery, anti-aging, and hormone-optimisation contexts, usually as part of a broader plan rather than a standalone product.
  • Because it is largely a research chemical with an unregulated supply chain, clinician oversight, sourcing transparency, and honest discussion of the limited evidence matter more than the name.
  • This page is informational only — it does not diagnose, prescribe, recommend CJC-1295, or provide dosing guidance.

Evidence at a glance

A scannable summary of what the current research and UK/US regulatory position actually show. Educational only — not medical advice, and no dosing guidance.

Evidence
Limited research only — no large long-term human trials. Descriptions of its GHRH-analogue mechanism should not be read as proven clinical benefits.
Human data
Insufficient. No large human trials establishing efficacy or long-term safety.
UK regulatory status
Not a licensed UK medicine. The MHRA treats it as an unlicensed substance, generally sold as a 'research chemical'.
US regulatory status
Never FDA-approved for any human use. Its US compounding status shifted during 2026 and remains an area of regulatory uncertainty.
Anti-doping (sport)
Prohibited in sport at all times — the WADA list specifically names GHRH analogues. Strict liability applies to athletes.

Last reviewed 13 August 2026. Regulatory status can change — always confirm the current position with a qualified clinician.

Clear intro

CJC-1295 pages attract users comparing growth-hormone and hormone-optimisation options. The strongest clinics explain the evidence limits, regulatory status, and the WADA ban honestly rather than marketing it as a simple growth-hormone boost.

Who this is for

This page is useful for people researching hormone-optimisation, performance, and recovery clinics that reference CJC-1295 — and for athletes who need to understand its anti-doping status.

What to ask before choosing a clinic

  • Why are you recommending CJC-1295, and why combined with ipamorelin?
  • What baseline testing and monitoring are included?
  • What does the evidence actually support, and what are realistic expectations?

Pricing and red flags

CJC-1295 pricing is usually part of a broader programme rather than a standalone figure. Compare the clinical oversight and monitoring included rather than the headline cost.

  • Guaranteed growth-hormone, anti-aging, or body-composition results.
  • No discussion of evidence limits, regulatory status, or the WADA ban.
  • No baseline assessment or monitoring before a protocol is discussed.

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) designed to prompt the pituitary gland to release more of the body's own growth hormone. It is not an approved medicine. It has never been FDA-approved for any human use; in the United States its compounding status shifted during 2026 and remains an area of regulatory uncertainty, and in the United Kingdom the MHRA treats it as an unlicensed substance generally sold as a 'research chemical'. It is also prohibited in sport at all times under the WADA list, which specifically names GHRH analogues. On clinic directories it is frequently discussed alongside ipamorelin.

How it works

As a GHRH analogue, CJC-1295 is intended to increase the pulses of growth hormone the body releases naturally, which can raise IGF-1. Most of the available information comes from limited research rather than large long-term human trials, so descriptions of mechanism should not be read as proven clinical benefits. For someone comparing clinics, what matters more is whether a provider explains the evidence limits and why CJC-1295 is being considered.

Typical use cases

  • Performance and recovery discussions, usually combined with ipamorelin rather than used alone.
  • Anti-aging and hormone-optimisation contexts, framed around growth-hormone support.
  • Body-composition pathways where it appears as one element of a broader, clinician-led plan.

Cost overview

CJC-1295 is usually bundled into a wider hormone, performance, or recovery programme — often combined with ipamorelin — so clinician involvement, monitoring, and sourcing transparency matter more than the headline figure. See the peptide therapy cost guide.

What to expect from clinics

  • A credible clinic should be clear that CJC-1295 is not an approved medicine, is banned in tested sport, and has limited long-term human evidence.
  • Expect a proper assessment, plus a clear explanation of sourcing, supervision, and follow-up before any protocol is discussed.
  • Be cautious of providers presenting it as risk-free or guaranteeing growth-hormone or anti-aging results.

Safety considerations

Because CJC-1295 is not an approved medicine and long-term human safety data is limited, its risks are not well characterised, and product quality varies across an unregulated supply chain. It is also banned in tested sport. Anyone considering it should do so only with a licensed clinician who can explain the evidence limits, regulatory and anti-doping status, and possible risks. This page does not recommend CJC-1295 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.

Frequently asked questions about CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue intended to prompt the body to release more of its own growth hormone. It is often discussed alongside ipamorelin in performance and anti-aging contexts.

Is CJC-1295 legal?

CJC-1295 is not an approved medicine. It has never been FDA-approved, the UK MHRA treats it as unlicensed, and it is generally sold as a 'research chemical' not intended for human consumption. Its US compounding status has been an area of regulatory uncertainty in 2026.

Is CJC-1295 banned in sport?

Yes. CJC-1295 is prohibited at all times under the WADA list, which specifically includes GHRH analogues. Any athlete subject to drug testing should treat it as banned.

Why is CJC-1295 used with ipamorelin?

Clinics often discuss the two together because they act on different parts of the growth-hormone pathway. Combining them does not make either one approved or risk-free — the same evidence and safety cautions apply.

What is the evidence behind CJC-1295?

Available information comes largely from limited research rather than large long-term human trials, so claims of proven growth-hormone or anti-aging benefits should be treated with caution.

Does Peptide Clinic Finder sell or recommend CJC-1295?

No. Peptide Clinic Finder is an informational directory. We do not sell CJC-1295, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.

Related comparisons: CJC-1295 vs Ipamorelin, CJC-1295 vs Sermorelin.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Related CJC-1295 pages

Move from peptide research into clinic comparisons, guides, and matching.

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering CJC-1295

The Catalyst Clinic logo
RecommendedVerified

The Catalyst Clinic

London, United Kingdom5.05.0 out of 5

Doctor-led peptide advisory consultations in central London. Every protocol is built around comprehensive bloodwork and personally led by Dr Ethan Hausman-Marquis, who reports a PhD from the Karolinska Institute, with compounds sourced from GMP-certified, EMA-regulated pharmacies.

  • Google 5.0 (48)
Doctor-led clinical governance

From £600

View Profile
Menon Health logo
FeaturedVerified

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

  • Google 3.7 (3)
GMC-registered physicians

From £195

View Profile
Levitas Clinic Mayfair London logo

Levitas Clinic Mayfair London

London, United Kingdom

Levitas Clinic Mayfair London is a specialist clinic listed on Peptide Clinic Finder in London, UK. Listed services are based on approved review evidence. It holds a 5.0-star Google rating from 105 reviews.

  • Google 5.0 (105)
View Profile

Explore clinics by city

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.

Next step

Explore suitable clinics

Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and programme structure than by peptide name alone.

Map preview
Mapbox map preview

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.